GLP-1 medications like Ozempic and Wegovy are touted for their ability to help with faster weight loss, but these meds may have other unintended benefits toward breast care, according to recent research.
A study of over 110,000 women led by researchers from the University of Pennsylvania in Philadelphia showed that GLP-1 use may cut women's breast cancer risk by 30%. The study was presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
Elizabeth McDonald, MD, joins this week's episode to discuss her team's results and what they could mean for women's breast care.
Elizabeth McDonald, MD, explains her team's findings showing how GLP-1 medications could help reduce breast cancer risk.
McDonald also talks about considerations and the mechanisms behind what could be causing this association. She also shares future research plans on GLP-1s and breast cancer.
Watch the full episode below.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
